TEL AVIV, Israel, November 15, 2016 /PRNewswire/ -- CannaTech has announced registration for its 3rd annual summit to take place in Tel Aviv, Israel, March 20-22, 2017. CannaTech will showcase the most current science, data and industry trends in medical cannabis today, highlighting new technologies, R&D and innovations that will guide the future of this multi-billion-dollar industry. Presentations will be given by international industry leaders from numerous disciplines--science, research, finance, agtech, government policy and regulation, Early bird tickets are on sale until December 18 and cost $420 for the two-day event. There is a separate fee for a third day of exclusive VIP travel touring. Early bird tickets can be purchased online at the event site http://www.canna-tech.co. Confirmed speakers include renowned Professor of Pharmacology, Psychiatry and Behavioral Sciences, Dr. Nephi Stella of the University of Washington, whose lab focuses on the role of cannabis and cutting edge neuroscience, and Cristina Sanchez, PhD, a molecular biologist at Compultense University in Madrid Spain, who leads groundbreaking research in the role of cannabis and cancer treatment. They will be joined by many of Israel's industry leaders among them Dr. David Meiri, leading cannabis researcher at the Technion, and iCAN: israel-cannabis CEO Saul Kaye. Kalytera Therapeutics are proud sponsors of CannaTech 2017. Kalytera is advancing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines. Dr. Raphael Mechoulam, the most influential figure in cannabis medicine to date, and former CannaTech keynote speaker, co-chairs their scientific leadership team.